SHANGHAI, Aug. 11 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced the appointment of Edward Hu as Chief Financial Officer effective immediately. Mr. Hu has served as the company's Chief Operating Officer since January 2008 and previously served as acting CFO from February 2009 through May 2010. Hao Zhou, the current CFO, is leaving WuXi to pursue other opportunities and will assist in the transition.
"I am confident that Ed's familiarity with our business and our industry and his previous tenure as acting CFO will enable him to lead our finance team to even better performance," commented Dr. Ge Li, Chairman and CEO. "We thank Hao for his contribution to building a strong finance team under Ed's leadership, and we wish him well in his future endeavors."
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
For more information, please contact: Stephanie Liu (for the media) Tel: +86-21-5046-4362 Email: email@example.com Ronald Aldridge (for investors) Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com
SOURCE WuXi PharmaTech